공고 • Mar 14
Moogene Medi Co., Ltd. announced that it expects to receive KRW 5 billion in funding from Yuhan Corporation Moogene Medi Co., Ltd. announced a private placement to issue Zero Coupon Series 2 Registered Interest-Backed Private Convertible Bonds due March 26, 2029 for gross proceeds of KRW 5,000,000,000 on March 12, 2026. The transaction will include participation from new investor Yuhan Corporation. The transaction has been approved by shareholders, expected to close on March 26, 2026, 100% convertible into 1,908,396 shares at a fixed conversion price of KRW 2,620 from March 26, 2027 to February 26, 2029, bears zero coupon rate, 3% maturity rate and matures on March 26, 2029. 공고 • Mar 10
Moogene Medi Co., Ltd., Annual General Meeting, Mar 31, 2026 Moogene Medi Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 25, misagangbyeonjungang-ro 7beonan-gil, gyeonggi-do, hanam South Korea 공고 • Mar 05
Moogene Medi Co., Ltd., Annual General Meeting, Mar 27, 2025 Moogene Medi Co., Ltd., Annual General Meeting, Mar 27, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 25, misagangbyeonjungang-ro 7beonan-gil, gyeonggi-do, hanam South Korea New Risk • Jun 27
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₩13.8b (US$9.95m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Market cap is less than US$10m (₩13.8b market cap, or US$9.95m). New Risk • Jun 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩16.9b market cap, or US$12.2m). New Risk • Feb 25
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (13% average weekly change). Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩27.5b market cap, or US$20.7m). New Risk • Jan 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Market cap is less than US$100m (₩18.6b market cap, or US$13.9m). 공고 • Apr 09
Moogene Medi Co., Ltd. announced that it expects to receive KRW 300 million in funding from MAGELLAN Technology Investment, Co., Ltd. Moogene Medi Co., Ltd. announced a private placement of 60,000 registered redeemable convertible preferred shares at a price of KRW 5,000 per share for gross proceeds of KRW 300,000,000 on April 7, 2022. The transaction will include participation from MTI Start-up 320 Fund, a fund managed by MAGELLAN Technology Investment, Co., Ltd. The company will receive funding through third party allotment of capital. The preferred shares are convertible into common shares from April 16, 2022 to April 16, 2032. The transaction has been approved by the board of directors of the company and is expected to close on April 15, 2022. The securities issued will be subject to restriction period of one year from issuance. 공고 • Mar 03
Moogene Medi Co., Ltd., Annual General Meeting, Mar 30, 2021 Moogene Medi Co., Ltd., Annual General Meeting, Mar 30, 2021, at 09:00 Korea Standard Time. Is New 90 Day High Low • Jan 05
New 90-day high: ₩6,400 The company is up 8.0% from its price of ₩5,940 on 07 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 21% over the same period.